Robert Iannone sold $19M of JAZZ
EVP, Global Head of R&D & CMO at Jazz Pharmaceuticals plc. 76,921 shares at an average of $249.70, traded Aug 27, 2026, filed Aug 31, 2026.
Score components
- +15RoleOfficer
- +25Trade size$19.2M at market
- +20Share of holdings soldSold 54% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001737329-26-000016, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | MOption exercise Ordinary Shares10b5-1 | +26,116 | $113.10 | $3.0M | 111,223 | 43 d ago |
| Aug 27, 2026 | MOption exercise Ordinary Shares10b5-1 | +884 | $113.10 | $100k | 112,107 | 43 d ago |
| Aug 27, 2026 | MOption exercise Ordinary Shares10b5-1 | +27,584 | $137.12 | $3.8M | 139,691 | 43 d ago |
| Aug 27, 2026 | MOption exercise Ordinary Shares10b5-1 | +2,916 | $137.12 | $400k | 142,607 | 43 d ago |
| Aug 27, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -18,187 | $247.86 | $4.5M | 124,420 | 43 d ago |
| Aug 27, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -11,423 | $248.67 | $2.8M | 112,997 | 43 d ago |
| Aug 27, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -18,113 | $250.02 | $4.5M | 94,884 | 43 d ago |
| Aug 27, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -19,639 | $250.60 | $4.9M | 75,245 | 43 d ago |
| Aug 27, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -9,259 | $251.95 | $2.3M | 65,986 | 43 d ago |
| Aug 27, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -300 | $252.76 | $76k | 65,686 | 43 d ago |
| Aug 27, 2026 | MOption exercise Incentive Stock Option (right to buy)derivative10b5-1 | -884 | $0.00 | $0 | 0 | 43 d ago |
| Aug 27, 2026 | MOption exercise Incentive Stock Option (right to buy)derivative10b5-1 | -2,916 | $0.00 | $0 | 0 | 43 d ago |
| Aug 27, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -26,116 | $0.00 | $0 | 0 | 43 d ago |
| Aug 27, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -27,584 | $0.00 | $0 | 0 | 43 d ago |
Related signals
Other insiders at Jazz Pharmaceuticals plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Jazz Pharmaceuticals plc | Renee D Gala President & CEO | $473k 2,000 shares | -1% | |
| 28Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.4M 6,000 shares | -2% | |
| 24Weak | Jazz Pharmaceuticals plc | Neena M Patil EVP & Chief Legal Officer | $289k 1,200 shares | -2% | |
| 38Weak | Jazz Pharmaceuticals plc | Renee D Gala President & CEO | $486k 2,000 shares | -1% | |
| 45Moderate | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.5M 6,000 shares | -2% | |
| 20Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.5M 6,000 shares | -2% | |
| 20Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.4M 6,000 shares | -2% | |
| 28Weak | Jazz Pharmaceuticals plc | Mark Douglas Smith director | $267k 1,157 shares | -11% | |
| 24Weak | Jazz Pharmaceuticals plc | Neena M Patil EVP & Chief Legal Officer | $278k 1,200 shares | -2% | |
| 35Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.4M 6,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.